Combined analysis of whole‐exon sequencing and lncRNA sequencing in type 2 diabetes mellitus patients with obesity. Issue 4 (19th January 2020)

• Record Type: Journal Article
• Authors: An, Tian; Zhang, Jing; Liu, Yu‐Fei; Wu, Yan‐Xiang; Lian, Juan; Wang, Ting‐Ye; Hu, Yuan‐yuan; Zhu, Jia‐jian; Huang, Jiangpinghao; Zhao, Dan‐Dan; Mo, Fang‐Fang; Gao, Si‐Hua; Jiang, Guang‐Jian
• Is Part Of: Journal of cellular and molecular medicine. Volume 24:Issue 4(2020)
• Page Start: 2451
• Page End: 2463
• Publication Date: 2020-01-19
• Subjects: diabetes -- long non‐coding RNA -- mutation sites -- obesity; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.14932
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: This study sought to find more exon mutation sites and lncRNA candidates associated with type 2 diabetes mellitus (T2DM) patients with obesity (O‐T2DM). We used O‐T2DM patients and healthy individuals to detect mutations in their peripheral blood by whole‐exon sequencing. And changes in lncRNA expression caused by mutation sites were studied at the RNA level. Then, we performed GO analysis and KEGG pathway analysis. We found a total of 277 377 mutation sites between O‐T2DM and healthy individuals. Then, we performed a DNA‐RNA joint analysis. Based on the screening of harmful sites, 30 mutant genes shared in O‐T2DM patients were screened. At the RNA level, mutations of 106 differentially expressed genes were displayed. Finally, a consensus mutation site and differential expression consensus gene screening were performed. In the current study, the results revealed significant differences in exon sites in peripheral blood between O‐T2DM and healthy individuals, which may play an important role in the pathogenesis of O‐T2DM by affecting the expression of the corresponding lncRNA. This study provides clues to the molecular mechanisms of metabolic disorders in O‐T2DM patients at the DNA and RNA levels, as well as biomarkers of the risk of these disorders.